Review article: insurance risks for patients with ulcerative colitis or Crohn's disease

Area of Science:

• Gastroenterology
• Epidemiology
• Actuarial Science

Background:

• Inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, has historically been associated with increased mortality and morbidity.
• Previous insurance risk assessments may have overestimated the long-term impact of IBD on patient outcomes.

Purpose of the Study:

• To re-evaluate the life expectancy, cancer risk, and working capacity of patients with ulcerative colitis and Crohn's disease.
• To inform more accurate insurance risk assessments for individuals with IBD.

Main Methods:

• Analysis of prospective, population-based studies examining mortality and health outcomes in patients with IBD.
• Comparison of standardized mortality ratios (SMR) between IBD patient cohorts and the general population.

Main Results:

• Many patients with ulcerative colitis and Crohn's disease exhibit normal life expectancy and working capacity.
• Mortality rates for ulcerative colitis are similar to or slightly less than the general population, with some exceptions in the first year post-diagnosis or for specific disease patterns.
• Mortality for Crohn's disease shows varied results, with some studies indicating a slight increase (SMR=1.4), while others show no overall increase except in specific circumstances like early diagnosis or multiple surgeries.

Conclusions:

• Insurance risk for IBD patients should be individualized based on disease extent, pattern, and patient-specific factors.
• Patients with ulcerative proctitis, left-sided colitis in remission, or localized Crohn's disease responding to treatment may have a good prognosis, challenging standard increased insurance premiums.